PMID- 38400155
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240227
IS  - 2076-393X (Print)
IS  - 2076-393X (Electronic)
IS  - 2076-393X (Linking)
VI  - 12
IP  - 2
DP  - 2024 Feb 7
TI  - MV130 in the Prevention of Recurrent Respiratory Tract Infections: A 
      Retrospective Real-World Study in Children and Adults.
LID - 10.3390/vaccines12020172 [doi]
LID - 172
AB  - Respiratory tract infections (RTIs) are among the most common and important 
      problems in clinical medicine, making antibiotics the gold standard therapeutic 
      option regardless of their frequent viral etiology. Their excessive and 
      inappropriate use contributes to the rapid rise of antibiotic resistance and 
      underscores the need for alternative strategies, especially when dealing with 
      recurrent RTIs. Prevention is the ideal alternative, but specific vaccines 
      targeting a wide range of respiratory pathogens are scarce. MV130 is a sublingual 
      bacterial vaccine that induces trained immunity and provides non-specific 
      protection against respiratory pathogens in various clinical settings according 
      to the concept of TIbV (Trained Immunity-based Vaccine). A retrospective 
      real-world study (RWS) was conducted to evaluate the annual incidence of RTIs and 
      the consumption of antibiotics before and after the administration of MV130, 
      using data sourced from the medical records of 599 patients (186 children and 413 
      adults) who suffered from recurrent RTIs. The median number of infectious 
      episodes in children was significantly reduced by more than 70% from 5 episodes 
      (interquartile range (IQR) 4.0-6.0) to 1 (IQR, 0.0-2.0) (p < 0.001) after MV130. 
      Similarly, in adults, the median number of episodes before MV130 immunization was 
      5 (IQR, 4.0-6.0), which dropped by more than 80% to 1 (IQR, 0.0-1.0) during the 
      year following MV130 immunization (p < 0.001). The median number of antibiotic 
      courses also significantly decreased for both children and adults by over 80% (p 
      < 0.001). This RWS showed that MV130 is an effective strategy for the prevention 
      of respiratory infections and the reduction of associated antibiotic consumption.
FAU - Montalban-Hernandez, Karla
AU  - Montalban-Hernandez K
AUID- ORCID: 0000-0002-1612-103X
AD  - Inmunotek S.L., 28805 Madrid, Spain.
FAU - Cogollo-Garcia, Ana
AU  - Cogollo-Garcia A
AD  - Inmunotek S.L., 28805 Madrid, Spain.
FAU - Giron de Velasco-Sada, Patricia
AU  - Giron de Velasco-Sada P
AD  - Inmunotek S.L., 28805 Madrid, Spain.
FAU - Caballero, Raquel
AU  - Caballero R
AD  - Inmunotek S.L., 28805 Madrid, Spain.
FAU - Casanovas, Miguel
AU  - Casanovas M
AUID- ORCID: 0000-0003-2330-3963
AD  - Inmunotek S.L., 28805 Madrid, Spain.
FAU - Subiza, Jose Luis
AU  - Subiza JL
AUID- ORCID: 0000-0002-0134-5321
AD  - Inmunotek S.L., 28805 Madrid, Spain.
FAU - Conejero, Laura
AU  - Conejero L
AUID- ORCID: 0000-0001-6515-9221
AD  - Inmunotek S.L., 28805 Madrid, Spain.
LA  - eng
PT  - Journal Article
DEP - 20240207
PL  - Switzerland
TA  - Vaccines (Basel)
JT  - Vaccines
JID - 101629355
PMC - PMC10893268
OTO - NOTNLM
OT  - MV130
OT  - lower respiratory tract infections
OT  - real world study
OT  - recurrent respiratory tract infections
OT  - respiratory tract infections
OT  - trained immunity-based vaccines
OT  - upper respiratory tract infections
COIS- All authors are Inmunotek S.L. employees.
EDAT- 2024/02/24 11:43
MHDA- 2024/02/24 11:44
PMCR- 2024/02/07
CRDT- 2024/02/24 01:23
PHST- 2023/12/06 00:00 [received]
PHST- 2024/01/25 00:00 [revised]
PHST- 2024/01/30 00:00 [accepted]
PHST- 2024/02/24 11:44 [medline]
PHST- 2024/02/24 11:43 [pubmed]
PHST- 2024/02/24 01:23 [entrez]
PHST- 2024/02/07 00:00 [pmc-release]
AID - vaccines12020172 [pii]
AID - vaccines-12-00172 [pii]
AID - 10.3390/vaccines12020172 [doi]
PST - epublish
SO  - Vaccines (Basel). 2024 Feb 7;12(2):172. doi: 10.3390/vaccines12020172.